Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) Short Interest Update

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) saw a significant decline in short interest in the month of March. As of March 15th, there was short interest totalling 2,400 shares, a decline of 55.6% from the February 28th total of 5,400 shares. Based on an average daily volume of 6,700 shares, the short-interest ratio is presently 0.4 days.

Santen Pharmaceutical Stock Performance

Shares of Santen Pharmaceutical stock traded up $0.03 during trading hours on Friday, hitting $9.66. The company’s stock had a trading volume of 2,103 shares, compared to its average volume of 10,166. The firm has a fifty day moving average of $9.58 and a 200-day moving average of $10.67. Santen Pharmaceutical has a twelve month low of $8.65 and a twelve month high of $13.00.

Santen Pharmaceutical Company Profile

Santen Pharmaceutical Co, Ltd. engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2a derivative which is marketing approval phase for the treatment of glaucoma and ocular hypertension.